Uncovering therapeutic targets for glioblastoma: a systems biology approach.
about
Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targetsCancer stem cells and radioresistanceCurrent Therapeutic Advances Targeting EGFR and EGFRvIII in GlioblastomaNuclear EGFRvIII-STAT5b complex contributes to glioblastoma cell survival by direct activation of the Bcl-XL promoter.Epidermal growth factor-induced enhancement of glioblastoma cell migration in 3D arises from an intrinsic increase in speed but an extrinsic matrix- and proteolysis-dependent increase in persistence.Incorporating molecular tools into early-stage clinical trialsAdvanced proteomic technologies for cancer biomarker discovery.The constitutive activity of epidermal growth factor receptor vIII leads to activation and differential trafficking of wild-type epidermal growth factor receptor and erbB23,3'-Diindolylmethane (DIM) inhibits the growth and invasion of drug-resistant human cancer cells expressing EGFR mutantsForced dimerization increases the activity of ΔEGFR/EGFRvIII and enhances its oncogenicity.Phosphotyrosine signaling analysis of site-specific mutations on EGFRvIII identifies determinants governing glioblastoma cell growthPhosphoproteomics and lung cancer research.Regulation of HGF expression by ΔEGFR-mediated c-Met activation in glioblastoma cellsQuantifying oncogenic phosphotyrosine signaling networks through systems biology.Activated epidermal growth factor receptor in ovarian cancer.Network medicine.Oncolytic adenovirus retargeted to Delta-EGFR induces selective antiglioma activityQuantitative phosphoproteomics by mass spectrometry: past, present, and futureTowards functional phosphoproteomics by mapping differential phosphorylation events in signaling networks.Designer therapies for glioblastoma multiforme.Quantitative analysis of cell signaling and drug action via mass spectrometry-based systems level phosphoproteomics.Selection criteria for c-Met-targeted therapies: emerging evidence for biomarkers.Receptor tyrosine kinases and their activation in melanoma.Aberrant signaling pathways in glioma.Prognostic and predictive biomarkers in adult and pediatric gliomas: toward personalized treatment.Phosphoproteomic studies of receptor tyrosine kinases: future perspectives.A survey of glioblastoma genomic amplifications and deletions.Acquired MET expression confers resistance to EGFR inhibition in a mouse model of glioblastoma multiforme.Gene- and viral-based therapies for brain tumorsQuantitative analysis of signaling networks across differentially embedded tumors highlights interpatient heterogeneity in human glioblastoma.Hyperactivation of constitutively dimerized oncogenic EGF receptors by autocrine loops.Plasma proteome profiling reveals biomarker patterns associated with prognosis and therapy selection in glioblastoma multiforme patients.
P2860
Q26829873-DC4FBD20-5FAF-4122-B0B4-26DD7E3C8FFBQ27008368-2B2FD6AA-0F20-46DC-8486-9DBA2363C4DEQ28087306-41077473-FD5F-48DA-8258-97B1AC1C5C54Q30416775-B3396BE3-4FDA-4D8B-A806-E7CACFE27CD7Q30483791-1CBE3EA7-90B2-4770-AEC0-ABDC6F8BD6BDQ33316159-EE748D1F-EB51-4C3E-AA5C-621A5DE6B684Q33433660-A81CE531-802B-4616-8441-A1F5B0BD4747Q33867510-EBEDAFB1-B3AD-4DE8-B75A-46CE7A4491DCQ33937876-3103A54D-ED6A-4C52-9AE1-7B55148E52ECQ35218835-EF6B5DF9-9239-4A63-BA5A-AEEBD27A0F82Q35793511-8787FCF4-36D5-4386-A760-80F7BBE95573Q36396425-43698341-8D4A-4B61-A3EF-4812874D74E8Q36567577-4E47363E-2174-4306-A8B1-F6F182583471Q36959749-FBA28E6C-6E45-4DAF-BD11-5EEFDED66F8AQ36981918-77B0BFAE-6E6D-434D-B56F-30E23F681F13Q37087536-2FE33ADB-E050-4EF4-868E-EAE90C1D1264Q37223357-55FBBAFF-FA7F-4703-A725-73DDB86CA0DEQ37240640-B3A1F6BF-8836-4ACA-AC55-CA84BC733336Q37313189-0EB21A30-57D6-40A3-A711-18A1981DA009Q37319650-6ABC32BC-6BD7-4B34-BA1B-8B4FE30072DAQ37417200-CEE591D7-90A5-4749-A17D-C898C380BF3CQ37730020-9656A8AD-54D1-46D2-B080-57EEA14909F5Q37841746-34B9F405-84F0-4A99-85C5-30A4FB0F80CCQ38161369-10A27767-7D9E-4ACA-BFA7-76D14FF65192Q38203283-D7880AD5-43C0-41D2-B950-9942D8A44760Q39434337-810E80CA-6134-42FD-9A4C-AE590C561873Q39824273-20AFDEDB-BCB4-495B-B0A2-EE452FED71C1Q41816118-3F187063-FF4D-444B-A5C2-9B6716568CCEQ42135456-F88219E5-82F2-4491-880F-5BB9AC150709Q42998414-4236871F-E750-4F1D-B4E9-BF67A9CDF96BQ47429409-67F0C60A-EAC9-4A93-B19B-341442D72D65Q55463617-94D45BD8-169D-4C80-A561-C0DC0139F779
P2860
Uncovering therapeutic targets for glioblastoma: a systems biology approach.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Uncovering therapeutic targets for glioblastoma: a systems biology approach.
@en
type
label
Uncovering therapeutic targets for glioblastoma: a systems biology approach.
@en
prefLabel
Uncovering therapeutic targets for glioblastoma: a systems biology approach.
@en
P356
P1433
P1476
Uncovering therapeutic targets for glioblastoma: a systems biology approach.
@en
P2093
Forest M White
Webster K Cavenee
P304
P356
10.4161/CC.6.22.4922
P577
2007-08-20T00:00:00Z